CL2019000429A1 - Conjugado de minoxidil y peptidos. - Google Patents

Conjugado de minoxidil y peptidos.

Info

Publication number
CL2019000429A1
CL2019000429A1 CL2019000429A CL2019000429A CL2019000429A1 CL 2019000429 A1 CL2019000429 A1 CL 2019000429A1 CL 2019000429 A CL2019000429 A CL 2019000429A CL 2019000429 A CL2019000429 A CL 2019000429A CL 2019000429 A1 CL2019000429 A1 CL 2019000429A1
Authority
CL
Chile
Prior art keywords
hair
composition
minoxidil
compound
growth
Prior art date
Application number
CL2019000429A
Other languages
English (en)
Inventor
Yong Ji Chung
Eun Mi Kim
Original Assignee
Caregen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caregen Co Ltd filed Critical Caregen Co Ltd
Publication of CL2019000429A1 publication Critical patent/CL2019000429A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN TIENE RELACIÓN CON UNA COMPOSICIÓN PARA PREVENIR LA PÉRDIDA DE CABELLO Y, MÁS ESPECÍFICAMENTE, A UN COMPUESTO QUE TIENE UNA ESTRUCTURA DONDE MINOXIDIL Y UN PÉPTIDO ESTÁN QUÍMICAMENTE CONECTADOS, Y A UNA COMPOSICIÓN FARMACÉUTICA O COMPOSICIÓN COSMÉTICA PARA PREVENIR LA PÉRDIDA DE CABELLO O PROMOVER EL CRECIMIENTO DEL CABELLO QUE COMPRENDE EL COMPUESTO. EL COMPUESTO QUE TIENE UNA ESTRUCTURA DONDE MINOXIDIL Y UN PÉPTIDO ESTÁN CONECTADOS QUÍMICAMENTE DE ACUERDO CON LA PRESENTE INVENCIÓN NO SÓLO TIENE UNA EXCELENTE ACTIVIDAD FISIOLÓGICA, COMO LA REDUCCIÓN DE LA PÉRDIDA DE CABELLO, LA PROMOCIÓN DEL CRECIMIENTO DEL CABELLO O LA PROMOCIÓN DEL CRECIMIENTO CELULAR, SINO TAMBIÉN UNA EXCELENTE ESTABILIDAD EN AGUA, Y POR LO TANTO PUEDE SER ÚTIL COMO UNA COMPOSICIÓN PARA PREVENIR LA CAÍDA DEL CABELLO Y PROMOVER EL CRECIMIENTO DEL CABELLO.
CL2019000429A 2016-08-19 2019-02-15 Conjugado de minoxidil y peptidos. CL2019000429A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160105707A KR101948238B1 (ko) 2016-08-19 2016-08-19 미녹시딜과 펩타이드의 결합체

Publications (1)

Publication Number Publication Date
CL2019000429A1 true CL2019000429A1 (es) 2019-04-26

Family

ID=61196895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000429A CL2019000429A1 (es) 2016-08-19 2019-02-15 Conjugado de minoxidil y peptidos.

Country Status (16)

Country Link
US (1) US11617796B2 (es)
EP (1) EP3501545B1 (es)
JP (2) JP7050052B2 (es)
KR (1) KR101948238B1 (es)
CN (1) CN109715217B (es)
AU (1) AU2017313589B2 (es)
BR (1) BR112019003077A2 (es)
CA (1) CA3034066C (es)
CL (1) CL2019000429A1 (es)
EA (1) EA038745B1 (es)
ES (1) ES2933848T3 (es)
MX (1) MX2019001921A (es)
MY (1) MY193527A (es)
PH (1) PH12019500345A1 (es)
WO (1) WO2018034453A1 (es)
ZA (1) ZA201901534B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089754B1 (ko) * 2018-11-09 2020-03-17 주식회사 바이오셀트란 피부투과성이 개선된 탈모 억제 또는 발모 촉진용 조성물
KR102221365B1 (ko) * 2019-05-07 2021-03-02 (주)케어젠 트롤록스-펩타이드 결합체 및 그의 용도
CN110755286A (zh) * 2019-11-18 2020-02-07 童婧 一种有助于生发的发际线填充组合物
JP7787381B2 (ja) * 2024-03-26 2025-12-17 オーチャード・バイオ株式会社 医薬組成物、及び粒子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
US6255313B1 (en) * 1997-01-23 2001-07-03 Taisho Pharmaceutical Co., Ltd. Sustained release hair growth composition
PT1103545E (pt) 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
FR2826262B1 (fr) 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un compose agissant sur la chute ou la repousse des cheveux
US20040142853A1 (en) 2002-11-07 2004-07-22 Procyte Corporation Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil
FR2857597B1 (fr) * 2003-07-18 2008-01-25 Inst Europeen Biolog Cellulair Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
KR101228239B1 (ko) * 2004-03-26 2013-01-30 디에스엠 아이피 어셋츠 비.브이. 화장품용 아릴알킬산의 아미노산 및 펩타이드 공액체
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
JP2009520739A (ja) * 2005-12-23 2009-05-28 アプラゲン ゲーエムベーハー ジスルフィド架橋の形成方法
KR101394768B1 (ko) * 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
KR101198918B1 (ko) * 2009-09-01 2012-11-07 (주)케어젠 Ｗｎｔ１０?유래 펩타이드 및 그의 용도
US20110306546A1 (en) 2010-06-10 2011-12-15 Alvi Armani Genomics Inc. Compositions for increasing hair growth and decreasing hair loss
KR20120011632A (ko) 2010-07-29 2012-02-08 애경산업(주) 미녹시딜을 함유한 모발 세정제 조성물 및 이의 제조 방법
MX353295B (es) * 2011-01-21 2018-01-08 Endo Kyoko Agente para el tratamiento de la alopecia.
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
FI3345613T3 (fi) 2015-09-01 2023-07-28 Il Dong Pharma Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin
KR102160566B1 (ko) 2019-01-16 2020-09-28 (주)케어젠 미녹시딜과 펩타이드의 결합체

Also Published As

Publication number Publication date
US20190192677A1 (en) 2019-06-27
MY193527A (en) 2022-10-18
AU2017313589A1 (en) 2019-03-07
JP2021080273A (ja) 2021-05-27
KR20180020789A (ko) 2018-02-28
JP7050052B2 (ja) 2022-04-07
BR112019003077A2 (pt) 2019-07-16
EA201990526A1 (ru) 2019-07-31
AU2017313589B2 (en) 2020-01-30
EP3501545B1 (en) 2022-10-26
JP2019528289A (ja) 2019-10-10
EA038745B1 (ru) 2021-10-13
WO2018034453A1 (ko) 2018-02-22
EP3501545A1 (en) 2019-06-26
US11617796B2 (en) 2023-04-04
ZA201901534B (en) 2022-05-25
CN109715217B (zh) 2022-07-29
CN109715217A (zh) 2019-05-03
EP3501545A4 (en) 2019-07-17
PH12019500345A1 (en) 2019-12-16
CA3034066A1 (en) 2018-02-22
CA3034066C (en) 2021-02-16
MX2019001921A (es) 2019-07-08
ES2933848T3 (es) 2023-02-14
KR101948238B1 (ko) 2019-02-14

Similar Documents

Publication Publication Date Title
CL2019000429A1 (es) Conjugado de minoxidil y peptidos.
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2019009020A (es) Metodo para reducir la neutropenia.
CO2022003608A2 (es) Cianopirrolidinas sustituidas con actividad como inhibidores de usp30
BR112015019064A2 (pt) métodos de tratamento de melanoma
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
MX2016007878A (es) Composicion farmaceutica que comprende adalimumab.
EA201600371A1 (ru) Гомополимер пропилена с низкой эмиссией
MY189759A (en) Conjugate of finasteride with peptide
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX383944B (es) Composiciones para el cuidado personal.
CL2015002914A1 (es) Tratamiento de la diabetes mellitus mediante formulaciones de la insulinas de acción prolongada
MX2017003117A (es) Particula tipo virus de flavivirus.
MX2016016148A (es) Preparacion de rocuronio con estabilidad mejorada.
CO2018007810A2 (es) Formulación líquida estable de gonadotropina
CY1119067T1 (el) Διασταυρουμενο υαλουρονικο οξυ, διαδικασια για την παρασκευη του και χρηση αυτου στο αισθητικο πεδιο
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
CO2017011964A2 (es) Un metodo para producir hcg recombinante
MX2016012248A (es) Composiciones para el tratamiento de autodigestion.
CR20150640S (es) Aparato para peinar el cabello
MX2018013556A (es) Polipeptidos variantes con rendimiento mejorado y uso de los mismos.